Factors influencing oral anticoagulant use in patients newly diagnosed with atrial fibrillation.
Age Factors
Aged
Aged, 80 and over
Anticoagulants
/ therapeutic use
Atrial Fibrillation
/ complications
Australia
Dabigatran
/ therapeutic use
Factor Xa Inhibitors
/ therapeutic use
Female
General Practice
Geography
Humans
Logistic Models
Male
Middle Aged
Practice Patterns, Physicians'
/ statistics & numerical data
Pyrazoles
/ therapeutic use
Pyridones
/ therapeutic use
Rivaroxaban
/ therapeutic use
Sex Factors
Stroke
/ etiology
Warfarin
/ therapeutic use
atrial fibrillation
oral anticoagulant
oral anticoagulant choice
oral anticoagulant initiation
primary care
Journal
European journal of clinical investigation
ISSN: 1365-2362
Titre abrégé: Eur J Clin Invest
Pays: England
ID NLM: 0245331
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
revised:
16
11
2020
received:
03
10
2020
accepted:
16
11
2020
pubmed:
23
11
2020
medline:
15
12
2021
entrez:
22
11
2020
Statut:
ppublish
Résumé
We investigated factors that influenced oral anticoagulant (OAC) initiation and choice in Australian general practice patients newly diagnosed with AF. Using an Australian nationally representative general practice dataset, MedicineInsight, we identified patients newly diagnosed with AF between January 2009 and April 2019. Logistic regression analyses were used to examine factors associated with OAC initiation and choice. A total of 63 212 patients with AF (53.7% males, mean age 72.4 years) were identified. Nearly two-thirds of these patients (40 854 [64.6%]) were initiated on an OAC, at a median time of 6 days after the documented diagnosis date. The proportion of patients who were initiated an OAC increased from 44.8% in 2009 to 72.2% in 2019 (P < .001). High risk of stroke (CHA The proportion of newly diagnosed patients with AF initiated on OAC increased markedly following the introduction of the DOACs. Of those initiated, 9 in 10 were receiving a DOAC at the end of the study period. There is potential underuse in women and individuals with dementia.
Sections du résumé
BACKGROUND
BACKGROUND
We investigated factors that influenced oral anticoagulant (OAC) initiation and choice in Australian general practice patients newly diagnosed with AF.
METHODS
METHODS
Using an Australian nationally representative general practice dataset, MedicineInsight, we identified patients newly diagnosed with AF between January 2009 and April 2019. Logistic regression analyses were used to examine factors associated with OAC initiation and choice.
RESULTS
RESULTS
A total of 63 212 patients with AF (53.7% males, mean age 72.4 years) were identified. Nearly two-thirds of these patients (40 854 [64.6%]) were initiated on an OAC, at a median time of 6 days after the documented diagnosis date. The proportion of patients who were initiated an OAC increased from 44.8% in 2009 to 72.2% in 2019 (P < .001). High risk of stroke (CHA
CONCLUSIONS
CONCLUSIONS
The proportion of newly diagnosed patients with AF initiated on OAC increased markedly following the introduction of the DOACs. Of those initiated, 9 in 10 were receiving a DOAC at the end of the study period. There is potential underuse in women and individuals with dementia.
Substances chimiques
Anticoagulants
0
Factor Xa Inhibitors
0
Pyrazoles
0
Pyridones
0
apixaban
3Z9Y7UWC1J
Warfarin
5Q7ZVV76EI
Rivaroxaban
9NDF7JZ4M3
Dabigatran
I0VM4M70GC
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13457Informations de copyright
© 2020 Stichting European Society for Clinical Investigation Journal Foundation. Published by John Wiley & Sons Ltd.
Références
Stroke Foundation Australia [Intenet]. Atrial fibrillation. Stroke Foundation. 15 January 2019, Accessed 15 January, 2019. https://strokefoundation.org.au/About-Stroke/Prevent-Stroke/Atrial%20fibrillation
Ball J, Thompson DR, Ski CF, Carrington MJ, Gerber T, Stewart S. Estimating the current and future prevalence of atrial fibrillation in the Australian adult population. Med J Aust. 2015;202(1):32-35.
Diouf I, Magliano DJ, Carrington MJ, Stewart S, Shaw JE. Prevalence, incidence, risk factors and treatment of atrial fibrillation in Australia: the Australian Diabetes, Obesity and Lifestyle (AusDiab) longitudinal, population cohort study. Int J Cardiol. 2016;205:127-132. https://doi.org/10.1016/j.ijcard.2015.12.013
Chugh Sumeet S, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation. Circulation. 2014;129(8):837-847. https://doi.org/10.1161/CIRCULATIONAHA.113.005119
Krijthe BP, Kunst A, Benjamin EJ, et al. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur Heart J. 2013;34(35):2746-2751. https://doi.org/10.1093/eurheartj/eht280
Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22(8):983-988.
Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly: the Framingham study. Arch Intern Med. 1987;147(9):1561-1564. https://doi.org/10.1001/archinte.1987.00370090041008
Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857-867.
January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014;130(23):e199-e267. https://doi.org/10.1161/cir.0000000000000041
Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955-962. https://doi.org/10.1016/s0140-6736(13)62343-0
Russo V, Attena E, Di Maio M, et al. Non-vitamin K vs vitamin K oral anticoagulants in patients aged > 80 year with atrial fibrillation and low body weight. Eur J Clin Invest. 2020;50(11):e13335. https://doi.org/10.1111/eci.13335
Ding WY, Lip GYH, Potpara TS. Atrial fibrillation: can it be as easy as CC to ABC? Eur J Clin Invest. 2020;50(11):e13413. https://doi.org/10.1111/eci.13413
Admassie E, Chalmers L, Bereznicki LR. Changes in oral anticoagulant prescribing for stroke prevention in patients with atrial fibrillation. Am J Cardiol. 2017;120(7):1133-1138. https://doi.org/10.1016/j.amjcard.2017.06.055
Busingye D, Gianacas C, Pollack A, et al. Data resource profile: medicineinsight, an Australian national primary health care database. Int J Epidemiol. 2019;48(6):1741-1741h. https://doi.org/10.1093/ije/dyz147
MedicineInsight, ed. MedicineInsight data book and data dictionary NPS MedicineWise; 2020.
Bezabhe WM, Bereznicki LR, Radford J, et al. Five-year trends in potential drug interactions with direct-acting oral anticoagulants in patients with atrial fibrillation: an Australian-wide study. J Clin Med. 2020;9(11):3568-https://doi.org/10.3390/jcm9113568
Castelino RL, Saunder T, Kitsos A, et al. Quality use of medicines in patients with chronic kidney disease. BMC Nephrol. 2020;21(1):216. https://doi.org/10.1186/s12882-020-01862-1
Bezabhe WM, Kitsos A, Saunder T, et al. Medication prescribing quality in australian primary care patients with chronic kidney disease. Journal of clinical medicine. 2020;9(3):783-https://doi.org/10.3390/jcm9030783
Socio-Economic Indexes for Areas (SEIFA) (Australian Bureau of Statistics) (2018).
4 Significant urban areas, urban centres and localities, section of state, July 2016 (Australian Bureau of Statistics) (2017).
Steffel J, Verhamme P, Potpara TS, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39(16):1330-1393. https://doi.org/10.1093/eurheartj/ehy136
O'Brien EC, Simon DN, Thomas LE, et al. The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation. Eur Heart J. 2015;36(46):3258-3264. https://doi.org/10.1093/eurheartj/ehv476
Simera I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting guidelines for health research. Eur J Clin Invest. 2010;40(1):35-53. https://doi.org/10.1111/j.1365-2362.2009.02234.x
Alamneh EA, Chalmers L, Bereznicki LR. The Tasmanian atrial fibrillation study: transition to direct oral anticoagulants 2011-2015. Cardiovasc Ther. 2017;35(3):2011-2015. https://doi.org/10.1111/1755-5922.12254
Brieger D, Amerena J, Attia J, et al. National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: Australian Clinical Guidelines for the Diagnosis and Management of Atrial Fibrillation 2018. Heart Lung Circ. 2018;27(10):1209-1266. https://doi.org/10.1016/j.hlc.2018.06.1043
January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Heart rhythm. 2019;16(8):e66-e93. https://doi.org/10.1016/j.hrthm.2019.01.024
Thompson LE, Maddox TM, Lei L, et al. Sex differences in the use of oral anticoagulants for atrial fibrillation: a report from the National Cardiovascular Data Registry (NCDR((R))) PINNACLE Registry. J Am Heart Assoc. 2017;6(7). https://doi.org/10.1161/jaha.117.005801
Lubitz SA, Khurshid S, Weng L-C, et al. Predictors of oral anticoagulant non-prescription in patients with atrial fibrillation and elevated stroke risk. Am Heart J. 2018;200:24-31. https://doi.org/10.1016/j.ahj.2018.03.003
Law SWY, Lau WCY, Wong ICK, et al. Sex-based differences in outcomes of oral anticoagulation in patients with atrial fibrillation. J Am Coll Cardiol. 2018;72(3):271-282. https://doi.org/10.1016/j.jacc.2018.04.066
Shantsila E, Wolff A, Lip GY, Lane DA. Gender differences in stroke prevention in atrial fibrillation in general practice: using the GRASP-AF audit tool. Int J Clin Pract. 2015;69(8):840-845. https://doi.org/10.1111/ijcp.12625
Hsu JC, Maddox TM, Kennedy K, et al. Aspirin instead of oral anticoagulant prescription in atrial fibrillation patients at risk for stroke. J Am Coll Cardiol. 2016;67(25):2913-2923. https://doi.org/10.1016/j.jacc.2016.03.581
Madhavan M, Holmes DN, Piccini JP, et al. Association of frailty and cognitive impairment with benefits of oral anticoagulation in patients with atrial fibrillation. Am Heart J. 2019;211:77-89. https://doi.org/10.1016/j.ahj.2019.01.005
Fanning L, Ryan-Atwood TE, Bell JS, et al. Prevalence, safety, and effectiveness of oral anticoagulant use in people with and without dementia or cognitive impairment: a systematic review and meta-analysis. J Alzheimers Dis. 2019;71(4):1375-1378. https://doi.org/10.3233/jad-199005
Flaker GC, Pogue J, Yusuf S, et al. Cognitive function and anticoagulation control in patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2010;3(3):277-283. https://doi.org/10.1161/CIRCOUTCOMES.109.884171
Delesie M, Knaepen L, Dendale P, et al. Effect of targeted education for atrial fibrillation patients: design of the EduCare-AF study. Eur J Clin Invest. 2020:e13442. https://doi.org/10.1111/eci.13442
Rose AJ, Goldberg R, McManus DD, et al. Anticoagulant prescribing for non-valvular atrial fibrillation in the veterans health administration. J Am Heart Assoc. 2019;8(17):e012646. https://doi.org/10.1161/jaha.119.012646
Li G, Lip GYH, Holbrook A, et al. Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies. Eur J Epidemiol. 2019;34(2):173-190. https://doi.org/10.1007/s10654-018-0415-7
Gonzalez-Chica DA, Vanlint S, Hoon E, Stocks N. Epidemiology of arthritis, chronic back pain, gout, osteoporosis, spondyloarthropathies and rheumatoid arthritis among 1.5 million patients in Australian general practice: NPS MedicineWise MedicineInsight dataset. BMC Musculoskelet Disord. 2018;19(1):20. https://doi.org/10.1186/s12891-018-1941-x
Radford J, Kitsos A, Stankovich J, et al. The epidemiology of chronic kidney disease in Australian general practice: National Prescribing Service MedicineWise MedicineInsight dataset. Nephrology. 2019. 24(7):1017-1025. https://doi.org/10.1111/nep.13537